Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
FDA priority review for Roche's Enspryng in rare autoimmune disorder signals regulatory catalyst.
What changed
FDA priority review for Roche's Enspryng in rare autoimmune disorder signals regulatory catalyst.
Why it matters
FDA priority review for Roche's Enspryng in rare autoimmune disorder signals regulatory catalyst. — impact context not separately stored; see What changed.
← Dashboard
Sep 10, 2026 04:20 PM ET